215 related articles for article (PubMed ID: 12827033)
1. Influence of two doses of irbesartan on non-dipper circadian blood pressure rhythm in salt-sensitive black hypertensives under high salt diet.
Polónia J; Diogo D; Caupers P; Damasceno A
J Cardiovasc Pharmacol; 2003 Jul; 42(1):98-104. PubMed ID: 12827033
[TBL] [Abstract][Full Text] [Related]
2. Influence of salt intake on the daytime-nighttime blood pressure variation in normotensive and hypertensive black subjects.
Damasceno A; Caupers P; Santos A; Lobo E; Sevene E; Bicho M; Polónia J
Rev Port Cardiol; 2000 Mar; 19(3):315-29. PubMed ID: 10804778
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic effect of angiotensin II receptor blockade in postmenopausal women on a high-sodium diet: A double-blind, randomized, placebo-controlled study.
Pechère-Bertschi A; Maillard M; Bischof P; Fathi M; Burnier M
Curr Ther Res Clin Exp; 2008 Dec; 69(6):467-79. PubMed ID: 24692821
[TBL] [Abstract][Full Text] [Related]
5. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
Coca A; Calvo C; Sobrino J; Gómez E; López-Paz JE; Sierra C; Bragulat E; de la Sierra A
Clin Ther; 2003 Nov; 25(11):2849-64. PubMed ID: 14693309
[TBL] [Abstract][Full Text] [Related]
6. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.
Leenen FH; Yuan B
Hypertension; 2001 Mar; 37(3):981-4. PubMed ID: 11244027
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertension.
Kawano Y; Sato Y; Yoshinaga K
Hypertens Res; 2008 Sep; 31(9):1753-63. PubMed ID: 18971554
[TBL] [Abstract][Full Text] [Related]
8. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
McIntyre M; MacFadyen RJ; Meredith PA; Brouard R; Reid JL
J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
11. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
12. Effects of potassium on blood pressure in salt-sensitive and salt-resistant black adolescents.
Wilson DK; Sica DA; Miller SB
Hypertension; 1999 Aug; 34(2):181-6. PubMed ID: 10454438
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
Lacourcière Y; Asmar R
Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
[TBL] [Abstract][Full Text] [Related]
15. Circadian rhythm of natriuresis is disturbed in nondipper type of essential hypertension.
Fujii T; Uzu T; Nishimura M; Takeji M; Kuroda S; Nakamura S; Inenaga T; Kimura G
Am J Kidney Dis; 1999 Jan; 33(1):29-35. PubMed ID: 9915264
[TBL] [Abstract][Full Text] [Related]
16. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
[TBL] [Abstract][Full Text] [Related]
17. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.
Tsunoda K; Abe K; Hagino T; Omata K; Misawa S; Imai Y; Yoshinaga K
Am J Hypertens; 1993 Jan; 6(1):28-32. PubMed ID: 8427658
[TBL] [Abstract][Full Text] [Related]
18. Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.
Wang TD; Tan RS; Lee HY; Ihm SH; Rhee MY; Tomlinson B; Pal P; Yang F; Hirschhorn E; Prescott MF; Hinder M; Langenickel TH
Hypertension; 2017 Jan; 69(1):32-41. PubMed ID: 27849566
[TBL] [Abstract][Full Text] [Related]
19. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
20. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
